Antibody Containment Development Generic Pharmaceutical 
The Pharma Data
JUNE 17, 2022
At Sandoz, we are constantly looking for ways to meet the changing needs of patients and health care providers,” said Florian Bieber, Global Head Biopharmaceuticals Development, Sandoz. “By About adalimumab Adalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody targeting tumor necrosis factor alpha (TNF-a).
The Pharma Data
APRIL 4, 2023
It has a leading global portfolio with eight marketed biosimilars and a further 15+ in various stages of development. About adalimumab Adalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody targeting tumor necrosis factor alpha (TNF-a). Our ambition is to be the world’s leading and most valued generics company.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
AUGUST 2, 2023
is a global pharmaceutical company, working across both developed and emerging markets. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Pfizer Inc.
The Pharma Data
DECEMBER 23, 2020
Agreement leverages Aurobindo’s existing development, commercial and manufacturing infrastructure. Commenting on the development, Mr. N. This vaccine has immense potential in eliminating shedding, and hence containing, the spread of the pandemic.” . HYDERABAD, India , Dec.
The Pharma Data
DECEMBER 23, 2020
company developing UB-612 a multitope peptide-based vaccine to fight COVID-19, today announced an exclusive agreement with Aurobindo Pharma to expand its global development and commercialization of UB-612 to India and the United Nations Children’s Fund (UNICEF) agency. Commenting on the development, Mr. N. HAUPPAUGE, N.Y.–(
Expert insights. Personalized for you.
52 
Let's personalize your content